Global Cell-Based Multiplex Assays Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Cell-Based Multiplex Assays Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Cell-based assays are used to understand gene, protein, or whole cell function and the regulatory mechanisms that control these functions, to screen for potential inhibitors or inducers of biological processes in drug development, or to localize effects or events within cells. Cell culture itself is also expensive. With multiplexing, fewer cells are required to obtain the same amount of data. Using the same cells for subsequent assays also ensures more accurate data. Multiplexing enables researchers to save money and time.

Market Overview:

The latest research study on the global Cell-Based Multiplex Assays market finds that the global Cell-Based Multiplex Assays market reached a value of USD 1563.57 million in 2022. It’s expected that the market will achieve USD 2532.13 million by 2028, exhibiting a CAGR of 8.37% during the forecast period.

Cell-Based Multiplex Assays are widely used in the pharmaceutical and biotechnology industries

Biopharmaceuticals refer to the treatment of diseases through the extraction of biologically effective components. Cell engineering is the most critical technology in biopharmaceuticals. It refers to the expansion and production of biological products based on animal cells in vitro, or their Used to discover and test new drugs. This method of rapidly culturing cells provides new ideas for biopharmaceuticals and promotes the overall development of biopharmaceuticals. Cell engineering is an important branch of biopharmaceuticals. It refers to the combination of cell, molecule, development, and genetic biology and other theories in application, and re-cultures on animal or plant cell tissues according to actual needs to make new pharmaceutical products. At present, many drugs in biopharmaceuticals rely on the support of cell engineering, such as antibiotics and vaccines, which play an important role in the prevention and treatment of diseases.
In the pharmaceutical industry, cell-based assays accelerate and enhance drug development to help bring therapeutics to market in a fast and efficient manner. The ability to analyze multiple markers in a multiplex assay provides additional information on drug MOA, drug efficacy, toxicity, and immunogenicity.
Therefore, Cell-Based Multiplex Assays are in high demand in the pharmaceutical and biotechnology industries.

Cell-Based Multiplex Assays are widely used in research institutes

Compared to biochemical assays, cell-based assays offer a complex and more biologically and physiologically relevant assay system because they are performed in a cellular environment that mimics disease states, preserves signaling pathways, and mimics drug responses. Therefore, Cell-Based Multiplex Assays become an important research tool.
For example, flow cytometry can help researchers quickly analyze individual cells in heterogeneous cell populations, and is frequently used in immunology, immuno-oncology, neurobiology, and many other research fields. Multiplexed flow cytometry analyzes multiple cellular properties using various fluorophores or dyes, making it a very dynamic and powerful flow cytometric analysis tool. Multiplex cell analysis technology can use different fluorescently labeled antibodies to identify different antigens on the surface and inside of cells in a single well of a microplate, and then use hydrodynamic focusing to make cells form a single stream of liquid flow through the laser beam, so as to collect each Multiple parameters of a cell. In addition, multiplex real-time PCR assays measure the abundance of extremely rare mutations associated with cancer.
Therefore, Cell-Based Multiplex Assays play an important role for researchers.

Region Overview:

In 2022, the share of the Cell-Based Multiplex Assays market in Americas stood at 42.54%.

Company Overview:

Thermo Fisher Scientific is one of the major players operating in the Cell-Based Multiplex Assays market, holding a share of 14.69% in 2023.

Thermo Fisher Scientific is an American provider of scientific instruments, reagents and consumables, and software services. Thermo Fisher Scientific manufactures scientific instruments, consumables, and chemicals. The company provides analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotechnology companies, hospitals and clinical diagnostic laboratories, universities, research institutions, and government agencies.

Promega Corporation is a leader in innovative solutions and technical support for the life sciences industry. The company's portfolio of more than 4,000 products supports a range of life science efforts in areas such as cell biology; DNA, RNA and protein analysis; drug development; human characterization and molecular diagnostics. For more than 40 years, the application of these tools and techniques has evolved, and today scientists and technicians use them in laboratories for academic and government research, forensics, pharmaceuticals, clinical diagnostics, and agricultural and environmental testing.

Agilent Technologies is a market leader in life sciences, diagnostics, and applied chemistry. The company provides instruments, services, consumables, applications, and expertise to laboratories worldwide. Agilent Technologies focuses its expertise on six key markets: food, environmental and forensics, pharmaceuticals, diagnostics, chemical and energy, and research.

Segmentation Overview:

By type, Flow Cytometry segment accounted for the largest share of market in 2022.

Application Overview:

The market's largest segment by application is the segment Pharmaceutical & Biotechnology Companies, with a market share of 61.65% in 2022.

Key Companies in the global Cell-Based Multiplex Assays market covered in Chapter 3:

Abcam
BD
Bio-Rad Laboratories
Promega Corporation
Thermo Fisher Scientific
Boster Biological Technology
R&D Systems
Meso Scale Discovery (MSD) 
Agilent Technologies

In Chapter 4 and Chapter 14.2, on the basis of types, the Cell-Based Multiplex Assays market from 2018 to 2029 is primarily split into:

Flow Cytometry
Fluorescence Detection
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Cell-Based Multiplex Assays market from 2018 to 2029 covers:

Pharmaceutical & Biotechnology Companies
Hospitals & Research Institutes
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)